ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2026 | $14.00 | Hold | TD Cowen |
| 10/28/2025 | $22.00 | Buy | Stifel |
| 1/22/2025 | $24.00 | Buy | Canaccord Genuity |
| 11/8/2024 | $18.00 → $24.00 | Hold → Buy | Stifel |
| 5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
| 10/20/2023 | $12.00 | Neutral | ROTH MKM |
| 9/12/2023 | Buy → Neutral | BTIG Research | |
| 9/12/2023 | Buy → Hold | Stifel |
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
Company to Host Conference Call on Tuesday, February 24, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 2236604. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. In
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Third quarter 2025 net sales of $205.6 million, including sales from M6 artificial cervical and lumbar discs, and pro forma net sales of $203.4 million, excluding sales from M6 discs, representing an increase of 5% on a reported basis and 6% on a
10-Q - Orthofix Medical Inc. (0000884624) (Filer)
8-K - Orthofix Medical Inc. (0000884624) (Filer)
SCHEDULE 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4 - Orthofix Medical Inc. (0000884624) (Issuer)
4/A - Orthofix Medical Inc. (0000884624) (Issuer)
TD Cowen initiated coverage of Orthofix with a rating of Hold and set a new price target of $14.00
Stifel resumed coverage of Orthofix with a rating of Buy and set a new price target of $22.00
Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Company to Host Conference Call on Tuesday, February 24, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 2236604. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. In
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Third quarter 2025 net sales of $205.6 million, including sales from M6 artificial cervical and lumbar discs, and pro forma net sales of $203.4 million, excluding sales from M6 discs, representing an increase of 5% on a reported basis and 6% on a
Company to Host Conference Call on Tuesday, November 4, 2025, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 5112586. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)